# Anish Thomas

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/anish-thomas/

## Facts

| Field | Value |
| --- | --- |
| Citations | 14,095 |
| Field | Lung Cancer Research Studies |
| h-index | 57 |
| i10-index | 135 |
| Last Known Institution | National Institutes of Health |
| OpenAlex ID | https://openalex.org/A5074644543 |
| ORCID iD | 0000-0003-3293-3115 |
| Works | 581 |

## Researcher papers

- [Cancer Statistics, 2002](https://scholariq.org/papers/cancer-statistics-2002/)
- [Antibody–drug conjugates for cancer therapy](https://scholariq.org/papers/antibody-drug-conjugates-for-cancer-therapy/)
- [Cancer treatments: Past, present, and future](https://scholariq.org/papers/cancer-treatments-past-present-and-future/)
- [Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline](https://scholariq.org/papers/treatment-of-malignant-pleural-mesothelioma-american-society-of-clinical/)
- [Refining the treatment of NSCLC according to histological and molecular subtypes](https://scholariq.org/papers/refining-the-treatment-of-nsclc-according-to-histological-and-molecular-subtypes/)
- [Targeting Topoisomerase I in the Era of Precision Medicine](https://scholariq.org/papers/targeting-topoisomerase-i-in-the-era-of-precision-medicine/)
- [Mesothelin Immunotherapy for Cancer: Ready for Prime Time?](https://scholariq.org/papers/mesothelin-immunotherapy-for-cancer-ready-for-prime-time/)
- [Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial](https://scholariq.org/papers/sunitinib-in-patients-with-chemotherapy-refractory-thymoma-and-thymic-carcinoma/)
- [Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression](https://scholariq.org/papers/major-cancer-regressions-in-mesothelioma-after-treatment-with-an-anti-mesothelin/)
- [Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial](https://scholariq.org/papers/molecular-profiling-and-targeted-therapy-for-advanced-thoracic-malignancies-a/)
- [Targeting genomic instability in extrapulmonary small cell neuroendocrine cancers: A phase II study with ATR inhibitor berzosertib and topotecan.](https://scholariq.org/papers/targeting-genomic-instability-in-extrapulmonary-small-cell-neuroendocrine/)

## Researcher topics

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Occupational and environmental lung diseases](https://scholariq.org/topics/occupational-and-environmental-lung-diseases/)
- [Cancer therapeutics and mechanisms](https://scholariq.org/topics/cancer-therapeutics-and-mechanisms/)

## Researcher university

- [National Institutes of Health](https://scholariq.org/institutions/national-institutes-of-health/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.